AAAAAA

   
Results: 1-14 |
Results: 14
Paclitaxel plus organoplatins: Still the gold standard in advanced ovariancancer?
Authors: Boccardo, F Miglietta, L Bruzzone, M Rubagotti, A Locatelli, MC Ragni, N
Citation: F. Boccardo et al., Paclitaxel plus organoplatins: Still the gold standard in advanced ovariancancer?, ANN ONCOL, 12(7), 2001, pp. 1023-1024
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study
Authors: Boccardo, F Rubagotti, A Amoroso, D Mesiti, M Romeo, D Caroti, C Farris, A Cruciani, G Villa, E Schieppati, G Mustacchi, G
Citation: F. Boccardo et al., Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study, J CL ONCOL, 19(22), 2001, pp. 4209-4215
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma
Authors: Santini, G Nati, S Spriano, M Gallamini, A Pierluigi, D Congiu, AM Truini, M Rubagotti, A Chisesi, T Vimercati, R Rossi, E Sertoli, MR Mattei, D Marino, G Gobbi, M
Citation: G. Santini et al., Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma, HAEMATOLOG, 86(3), 2001, pp. 282-286
Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial
Authors: Ballestrero, A Rubagotti, A Stura, P Ferrando, F Amoroso, D Rinaldini, M Sismondi, P Genta, F Mesiti, M Brema, F Patrone, F Boccardo, F
Citation: A. Ballestrero et al., Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial, ONCOL-BASEL, 60(3), 2001, pp. 221-227
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. (vol 95, pg 260, 2001)
Authors: Boccardo, F Marenghi, C Ghione, G Pepe, A Parodi, S Rubagotti, A
Citation: F. Boccardo et al., Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. (vol 95, pg 260, 2001), INT J CANC, 95(6), 2001, pp. 398-398
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast
Authors: Boccardo, F Marenghi, C Ghione, G Pepe, A Parodi, S Rubagotti, A
Citation: F. Boccardo et al., Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast, INT J CANC, 95(4), 2001, pp. 260-265
Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer? In reply
Authors: Boccardo, F Rubagotti, A
Citation: F. Boccardo et A. Rubagotti, Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer? In reply, J CL ONCOL, 18(2), 2000, pp. 449-450
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial
Authors: Boccardo, F Rubagotti, A Amoroso, D Mesiti, M Romeo, D Sismondi, P Giai, M Genta, F Pacini, P Distante, V Bolognesi, A Aldrighetii, D Farris, A
Citation: F. Boccardo et al., Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial, J CL ONCOL, 18(14), 2000, pp. 2718-2727
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group
Authors: Santini, G Coser, P Congiu, AM Salvagno, L De Souza, C Sertoli, MR Olivieri, A Chisesi, T Rubagotti, A Truini, M Contu, A Porcellini, A Zambaldi, G Nati, S Marino, G Rizzoli, V
Citation: G. Santini et al., VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group, HAEMATOLOG, 85(2), 2000, pp. 160-166
High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow
Authors: Santini, G De Souza, C Congiu, AM Nati, S Marino, G Soracco, M Sertoli, MR Rubagotti, A Spriano, M Vassallo, F Rossi, E Vimercati, R Piaggio, G Figari, O Benvenuto, F Abate, M Truini, M Ravetti, JL Ribizzi, I Damasio, E
Citation: G. Santini et al., High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow, LEUK LYMPH, 33(3-4), 1999, pp. 321-330
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study
Authors: Boccardo, F Rubagotti, A Borichello, M Battaglia, M Carmignani, G Comeri, G Conti, G Cruciani, G Dammino, S Delliponti, U Ditonno, P Ferraris, V Lilliu, S Montefiore, F Portoghese, F Spano, G
Citation: F. Boccardo et al., Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study, J CL ONCOL, 17(7), 1999, pp. 2027-2038
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients
Authors: Boccardo, F Rubagotti, A Amoroso, D Agostara, B Amadori, D Gallo, L Iacobelli, S Massidda, B Mesiti, M Pacini, P Tomao, S Paganuzzi, M Marroni, P
Citation: F. Boccardo et al., Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients, CANC CHEMOT, 43(6), 1999, pp. 461-466
Autografting with Philadelphia chromosome-negative mobilized hematopoieticprogenitor cells in chronic myelogenous leukemia
Authors: Carella, AM Lerma, E Corsetti, MT Dejana, A Basta, P Vassallo, F Abate, M Soracco, M Benvenuto, F Figari, O Podesta, M Piaggio, G Ferrara, R Sessarego, M Parodi, C Pizzuti, M Rubagotti, A Occhini, D Frassoni, F
Citation: Am. Carella et al., Autografting with Philadelphia chromosome-negative mobilized hematopoieticprogenitor cells in chronic myelogenous leukemia, BLOOD, 93(5), 1999, pp. 1534-1539
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha inrenal cell carcinoma. A randomized phase II trial
Authors: Boccardo, F Rubagotti, A Canobbio, L Galligioni, E Sorio, R Lucenti, A Cognetti, F Ruggeri, E Landonio, G Baiocchi, C Besana, C Citterio, G De Rosa, M Calabresi, F
Citation: F. Boccardo et al., Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha inrenal cell carcinoma. A randomized phase II trial, TUMORI, 84(5), 1998, pp. 534-539
Risultati: 1-14 |